Is Personalis profitable in 2026?

No. Personalis guided FY2026 net loss of about $105M and cash usage near $100M, with cash falling from roughly $240M at end of FY2025 to $73.6M by end of Q1 2026, per its May 8, 2026 earnings call.

Is Personalis being acquired?

Yes. On July 20, 2026, Tempus AI announced a definitive agreement to acquire all outstanding Personalis shares at $16.25 per share, a stock-heavy deal valuing Personalis at roughly $1.5 to $1.9 billion, expected to close late 2026 or early 2027.

Who is Personalis's biggest competitor?

Natera's Signatera test is the market leader in molecular residual disease testing by coverage breadth and oncologist adoption, ahead of Personalis's NeXT Personal, even as Personalis grew clinical test volume 258% year over year in Q1 2026.

Could AI replace Personalis?

Unlikely directly. Personalis's value sits in its CLIA-certified lab, proprietary NeXT Personal assay, and four Medicare coverage decisions won through 2026, assets AI cannot replicate. Instead, acquirer Tempus AI is consolidating the business into its own platform as of July 20, 2026.

How fast is Personalis's clinical testing business growing?

Clinical test volume hit 7,815 in Q1 2026, up 258% year over year and 26% sequentially, per the May 8, 2026 earnings call. FY2026 guidance (May 7, 2026) targets 43,000 to 45,000 clinical tests, about 171% growth at midpoint.

Why did Personalis stock drop after the Tempus deal news?

PSNL shares fell about 14.6% on July 20, 2026, after Tempus AI's $16.25 per share, stock-heavy acquisition offer with a capped exchange ratio was announced, as merger-arbitrage traders discounted the floating-ratio deal structure.

Biotech tools companies · acquisition pending · United States

Personalis

personalis.com ↗

Genomic testing company for cancer MRD detection, now being bought by Tempus AI.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from late 2026 or early 2027 · Every call on the record Checkpoint: Shareholder vote and regulatory clearance for Tempus AI acquisition expected to close

The call

Personalis now moves forward as a Tempus AI acquisition target, with its independent fate replaced by the terms and timing of that deal.

Personalis makes blood tests that detect cancer early by looking for tumor DNA. It has hard-to-get government approvals and insurance coverage that took years to build, but Natera's similar test (called Signatera) is already more popular with doctors. The biggest change to watch is whether Tempus AI, the company buying Personalis, can actually close the deal and then combine both companies into one platform that works better together. If that fails or gets delayed, the whole investment case falls apart.

Why

AI pressure: Tempus AI. Tempus is not attacking from outside, it is buying Personalis outright to fold its tests into its own AI data platform. Could AI do the core job? Unlikely.

Bigger players: Natera (Signatera). Signatera already leads on coverage breadth and oncologist adoption, leaving Personalis as the smaller player even before the buyout. Could a giant copy it? No, they are blocked.

What protects it. Four locked CMS coverage decisions and a CLIA lab give Personalis reimbursement rates and clinical trust that are hard to duplicate fast.

What would change this call

Whether the Tempus AI acquisition of Personalis closes at or near the announced $16.25/share terms. Confirms the deal proceeds as planned rather than repricing or breaking.
Tempus AI (TEM) stock price stability through and after deal close. Determines actual payout value given the capped floating exchange ratio.
Personalis FY2026 clinical revenue hitting the guided $10-11M (5x YoY) range. Shows whether Medicare-covered test growth is materializing as promised.

Key numbers

FY2025 revenue $84.6M (2026-02-26)
Cash fell to $73.6M by Q1 2026 (2026-05-08)
FY2026 guided net loss ~$105M (2026-05-08)

Named risks

Tempus acquisition could break or reprice, leaving Personalis facing standalone liquidity crisis. Severity: high
Cash fell from ~$240M to $73.6M in one quarter against a guided $100M FY2026 cash use. Severity: high
Natera's Signatera holds stronger coverage breadth and adoption, limiting Personalis's independent market position. Severity: medium
Regulatory/antitrust review could delay merger close beyond expected late 2026/early 2027 window. Severity: medium
Litigious MRD sector (e.g. Natera-Guardant $292.5M verdict) signals aggressive competitive spillover risk. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Natera (Signatera)	losing to	Signatera leads MRD market by coverage breadth and oncologist adoption as of 2026, ahead of NeXT Personal
Guardant Health	contesting	Won $292.5M jury verdict against Natera for false advertising in MRD space, Nov 25 2024
Tempus AI	gaining on	Moved from ~19.3% stakeholder in Aug 2024 to full acquirer via definitive deal on Jul 20 2026

Questions people ask

Is Personalis profitable in 2026?: No. Personalis guided FY2026 net loss of about $105M and cash usage near $100M, with cash falling from roughly $240M at end of FY2025 to $73.6M by end of Q1 2026, per its May 8, 2026 earnings call.
Is Personalis being acquired?: Yes. On July 20, 2026, Tempus AI announced a definitive agreement to acquire all outstanding Personalis shares at $16.25 per share, a stock-heavy deal valuing Personalis at roughly $1.5 to $1.9 billion, expected to close late 2026 or early 2027.
Who is Personalis's biggest competitor?: Natera's Signatera test is the market leader in molecular residual disease testing by coverage breadth and oncologist adoption, ahead of Personalis's NeXT Personal, even as Personalis grew clinical test volume 258% year over year in Q1 2026.
Could AI replace Personalis?: Unlikely directly. Personalis's value sits in its CLIA-certified lab, proprietary NeXT Personal assay, and four Medicare coverage decisions won through 2026, assets AI cannot replicate. Instead, acquirer Tempus AI is consolidating the business into its own platform as of July 20, 2026.
How fast is Personalis's clinical testing business growing?: Clinical test volume hit 7,815 in Q1 2026, up 258% year over year and 26% sequentially, per the May 8, 2026 earnings call. FY2026 guidance (May 7, 2026) targets 43,000 to 45,000 clinical tests, about 171% growth at midpoint.
Why did Personalis stock drop after the Tempus deal news?: PSNL shares fell about 14.6% on July 20, 2026, after Tempus AI's $16.25 per share, stock-heavy acquisition offer with a capped exchange ratio was announced, as merger-arbitrage traders discounted the floating-ratio deal structure.

Timeline

2026-07-20Tempus AI announces definitive agreement to acquire Personalis at $16.25/share, ~$1.5-1.9B
2026-07-20PSNL shares fall ~14.6% on deal announcement
2026-05-20Personalis secures fourth Medicare coverage decision, neoadjuvant breast cancer monitoring
2026-05-08Q1 2026 results: cash falls to $73.6M, clinical volume up 258% YoY
2026-05-07Personalis reaffirms FY2026 guidance including 5x clinical revenue growth
2026-02-26FY2025 results: total revenue $84.6M, cash ~$240M
2026-02-18Medicare coverage granted for NeXT Personal in lung cancer surveillance
2025-11-25CMS sets reimbursement rates of $4,266 and $1,164 for NeXT Personal, effective Dec 1
2025-11-10Medicare coverage granted for NeXT Personal in breast cancer surveillance
2024-08-16Tempus AI expands stake in Personalis to ~19.3%
2023-12-05Personalis cuts 65 jobs, about 20% of workforce

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation